MSD and Daiichi Sankyo have announced first subject dosing in the IDeate-Prostate01 Phase III trial of ifinatamab deruxtecan ...

Merck and Daiichi Sankyo have announced that the first patient has been dosed in the IDeate-Prostate01 phase 3 trial ...

Merck just kicked off its Phase 3 IDeate-Prostate01 trial, handing the first dose of ifinatamab deruxtecan to a patient ...

The first patient has been dosed in the IDeate-Prostate01 phase 3 trial evaluating the efficacy and safety of investigational ifinatamab deruxtecan (I-DXd) versus docetaxel in patients with metastatic ...

The crystal structure of B7-consists of a unique combination of two Ig domains. One is characteristic of an adhesion receptor and the other has only been seen previously in antigen receptors 25.

Currently, the debate is purportedly set to take place on both the H3 Podcast and Piker's Twitch stream on Friday, May 2nd, 2025 at 12:30 PST. On April 23rd, 2025, Ethan Klein said during an episode ...